Evidence map›Paper›PMID 26660488›Full record

ArticleObesity surgery2016

Laparoscopic Sleeve Gastrectomy: Co-morbidity Profiles and Intermediate-Term Outcomes.

Jonathan S Abelson, Cheguevera Afaneh, Patrick Dolan, Genevevie Chartrand, Gregory Dakin, Alfons Pomp

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02947412 (Long Term Results After Sleeve Gastrectomy as a Primary Procedure in Obesity Surgery), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02947412 completednot on this map

Long Term Results After Sleeve Gastrectomy as a Primary Procedure in Obesity Surgery

TypeobservationalSponsorSana Klinikum OffenbachRan2007 to 2016Enrolled40ConditionsObesityArmslaparoscopic sleeve gastrectomy
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonathan S AbelsonDepartment of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA.
Cheguevera AfanehDepartment of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA. cha9043@med.cornell.edu.
Patrick DolanDepartment of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA.
Genevevie ChartrandDepartment of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA.
Gregory DakinDepartment of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA.
Alfons PompDepartment of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBariatric surgery is effective at achieving sustained weight loss and improving the control and resolution of obesity-related co-morbidities. Most studies that have demonstrated co-morbidity resolution in patients undergoing laparoscopic sleeve gastrectomy (LSG) only follow patients for the short term (less than 1 year) or follow a relatively small cohort (<100 patients) for the intermediate or long term (more than 5 years). We report our experience following a large cohort of morbidly obese patients who underwent LSG with intermediate-term follow-up.

methodsWe retrospectively reviewed 435 consecutive patients who underwent LSG from January 2004 to November 2013. Co-morbidities investigated included diabetes mellitus (DM), hypertension (HTN), and hyperlipidemia (HL). A co-morbidity was determined to be resolved if the patient was no longer taking any medication to treat that specific co-morbidity.

resultsMean follow-up was 26 ± 25 months (range = 1-112). Mean postoperative total weight loss (%TWL) at 6, 12, 24, 36, 48, 60, and 72 months were 23.6, 29.9, 29.5, 25.2, 26.7, 25.4, and 24.3 %, respectively. The incidence of all three co-morbidities was found to be significantly lower at the last patient follow-up. The resolution rates for DM, HTN, and HL were 59, 31, and 50 %, respectively. In patients who continued to have co-morbidities, the mean numbers of medications for DM (1.2 ± 0.7 vs. 0.5 ± 0.7, p < 0.0001), HTN (1.8 ± 1.1 vs. 1.3 ± 1.2, p < 0.0001), and HL (0.9 ± 0.7 vs. 0.6 ± 0.6, p < 0.0001) postoperatively were all significantly less.

conclusionsLSG is effective at achieving significant and sustained weight loss, improvement in co-morbidity profiles, and a reduction in poly-pharmacy for these conditions over intermediate-term follow-up.

Indexed as

AdultComorbidityDiabetes Mellitus, Type 2FemaleGastrectomyHumansHyperlipidemiasHypertensionLaparoscopyMaleObesity, MorbidPostoperative PeriodRetrospective StudiesTreatment OutcomeWeight LossBariatric surgeryCo-morbidity resolutionIntermediate-term follow-upLaparoscopic sleeve gastrectomyWeight loss

Identifiers

PMID26660488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.